The next breakthrough came in 2019 with trastuzumab deruxtecan (DS-8201), which achieved unprecedented efficacy, including in HER2-low breast cancer, by combining a cleavable tetrapeptide linker with a membrane-permeable topoisomerase I inhibitor payload [9]. Here, ERBB2 is linked to breast carcinoma.